Skip to main content

Table 2 Association between quality of response and body mass index clustered by standard WHO categories in patients with relapsed and refractory classical Hodgkin lymphoma treated with nivolumab monotherapy

From: Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab

  

No. of responses (%)

 

BMI

No. patients

CR

PR

SD

PD

P *

Underweight

12

4 (41.7)

4 (33.3)

1 (8.3)

2 (16.7)

 

Normal weight

66

20 (30.3)

29 (43.9)

12 (18.2)

5 (7.6)

 

Overweight

31

10 (32.9)

15 (48.4)

2 (6.5)

4 (12.9)

0.5

Obese

24

4 (16.7)

11 (45.8)

4 (16.7)

5 (20.8)

 
  1. BMI body mass index according to WHO categorization, CR complete response, PR partial response, SD stable disease, PD progressive disease
  2. *Pearson Chi-Square